As CML LSCs are more metabolically active than normal HSCs, we hypothesized that at least some of this activity was mediated by BCR::ABL1 kinase activity and would therefore be reversed following TKI treatment. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.